Answers are grounded in this paper and cite their sources.
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
No takes yet. Share an insight, caveat, or question.
Paz‐Ares et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: